Screener
Harrow HROW Compounding — Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | Branded | Compounding | Consolidated |
|---|---|---|---|
| Product sales, net | $30,631,000 | $13,499,000 | $44,130,000 |
| Other revenues | 73,000 | - | 73,000 |
| Total revenues | 30,704,000 | 13,499,000 | 44,203,000 |
| Cost of sales | 10,954,000 | 6,204,000 | 17,158,000 |
| Gross profit | 19,750,000 | 7,295,000 | 27,045,000 |
| Operating expenses | |||
| Selling, general and administrative | 25,759,000 | 6,742,000 | 32,501,000 |
| Research and development | 5,621,000 | 210,000 | 5,831,000 |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's compounding — revenue?
- Harrow (HROW) reported compounding — revenue of $13.5M in Q1 2026.
- How has Harrow's compounding — revenue changed year-over-year?
- Harrow's compounding — revenue decreased by 32.7% year-over-year, from $20.05M to $13.5M.
- What does compounding — revenue mean?
- This metric represents the total net revenue generated from the sale of compounded ophthalmic pharmaceutical products to customers, excluding any collected sales taxes. It serves as a primary indicator of market demand and commercial success within the company's specialized compounding business segment. Tracking this figure helps investors evaluate the scale and growth trajectory of the compounding product portfolio.
Ask your AI about Harrow's compounding — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude